Skip to content

Prospective comparative randomized study of procedural sedation during TAVR (Transcatheter Aortic Valve Replacement)

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-511018-18-00
Enrollment
1
Registered
2024-07-01
Start date
2024-08-09
Completion date
Unknown
Last updated
2024-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with aortic stenosis underwent transcatheter aortic valve replacement

Brief summary

Incidence of respiratory acidosis: Defined as pH<7.35 and an increase in PaCO2 compared to baseline, measured through serial arterial blood gas analysis during the procedure., Incidence of emergence delirium: Assessed through the administration of the CAM-ICU (Confusion Assessment Method for the Intensive Care Unit) within the first 24 hours following the end of the procedure.

Detailed description

The assessment of sedation effectiveness includes: - Time to achieve the desired sedation target (from the start of sedation to reaching a Richmond Agitation Sedation Scale of -2/-3). - Time to meet discharge criteria from the operating room (from sedation cessation to achieving an Aldrete's scoring system score >9). - Incidence of agitation episodes (RASS > +1). - Intraprocedural need to deviate from the established protocol beyond the therapeutic ranges indicated., The assessment of the incidence of intra-procedural adverse events includes: - Incidence of respiratory events (desaturation, need for supplemental oxygen, loss of respiratory drive, need for mask ventilation, respiratory acidosis with pH<7.35 and an increase in PaCO2 compared to baseline). - Incidence of hemodynamic events (hypotension, bradycardia, need for vasopressor support)., The evaluation of post-operative adverse events includes: - Total duration of hospitalization. - Incidence of post-operative cognitive decline (changes in Mini Mental State postoperative compared to baseline).

Interventions

DRUGRemifentanil Mylan 1 mg
DRUGDexmedetomidina Ever Pharma 100 microgrammi/ml concentrato per soluzione per infusione
DRUGPropofol Kabi 10 mg/ml emulsione iniettabile o per infusione

Sponsors

Azienda Socio Sanitaria Territoriale Ovest Milanese
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Incidence of respiratory acidosis: Defined as pH<7.35 and an increase in PaCO2 compared to baseline, measured through serial arterial blood gas analysis during the procedure., Incidence of emergence delirium: Assessed through the administration of the CAM-ICU (Confusion Assessment Method for the Intensive Care Unit) within the first 24 hours following the end of the procedure.

Secondary

MeasureTime frame
The assessment of sedation effectiveness includes: - Time to achieve the desired sedation target (from the start of sedation to reaching a Richmond Agitation Sedation Scale of -2/-3). - Time to meet discharge criteria from the operating room (from sedation cessation to achieving an Aldrete's scoring system score >9). - Incidence of agitation episodes (RASS > +1). - Intraprocedural need to deviate from the established protocol beyond the therapeutic ranges indicated., The assessment of the incidence of intra-procedural adverse events includes: - Incidence of respiratory events (desaturation, need for supplemental oxygen, loss of respiratory drive, need for mask ventilation, respiratory acidosis with pH<7.35 and an increase in PaCO2 compared to baseline). - Incidence of hemodynamic events (hypotension, bradycardia, need for vasopressor support)., The evaluation of post-operative adverse events includes: - Total duration of hospitalization. - Incidence of post-operative cognitive decline

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026